Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis

BACKGROUND: Osteosarcoma commonly develops during childhood and adolescence. Only one-third of osteosarcoma patients have been clinically detected over the age of 40 years, and the survivorship of those patients is quite dismal. Apatinib, a novel multitarget angiogenesis inhibitor, has shown a short...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Taojun, Huang, Qi, Tang, Fan, Wang, Yitian, Li, Zhuangzhuang, Luo, Yi, Min, Li, Zhou, Yong, Tu, Chongqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664205/
https://www.ncbi.nlm.nih.gov/pubmed/36387068
http://dx.doi.org/10.3389/fonc.2022.1031787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664205/
https://www.ncbi.nlm.nih.gov/pubmed/36387068
http://dx.doi.org/10.3389/fonc.2022.1031787

Ejemplares similares